Marina Cler
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Marina Cler has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Elena Martínez
Institute for Bioengineering of Catalonia
2 shared publications - Elisabeth Engel
Institute for Bioengineering of Catalonia, Barcelona, Spain
2 shared publications - Anna Laromaine
Institut de Ciència de Materials de Barcelona, ICMAB-CSIC, Bellaterra 08193, Spain
1 shared publication - Antonio Rodríguez-Sinovas
Cardiovascular Diseases Research Group, Vall d’Hebron Institute of Research (VHIR) and Universitat Autònoma de Barcelona, Instituto de Investigación Sanitaria Hospital Universitario Vall d’Hebron (IIS IR-HUVH), 08035 Barcelona, Spain
1 shared publication - Bernhard Dörling
Institut de Ciència de Materials de Barcelona (ICMAB-CSIC) , Carrer dels Til.lers
1 shared publication - Cesare Mn Terracciano
National Heart and Lung Institute, Imperial College London, London, United Kingdom
1 shared publication
Latest Publications
- Open Access
L-lactic acid induces short- and long-term cardioprotective effects through MCT1 transport, induction of metabolic reprogramming, and gene expression modulation
Lactic acid is recognized as an alternative fuel source for various tissues and is acknowledged for its protective effects in the brain. However, its potential as a cardioprotective agent remains controversial. Here, we aimed to (1) evaluate the impact of acute L-lactic acid administration, given at the onset of reperfusion, on myocardial infarct size in isolated mouse hearts submitted to transient global ischemia, (2) assess the effects of chronic L-lactic acid exposure in living myocardial slices (LMS) from human hearts, and (3) elucidate the underlying mechanisms. Isolated mouse hearts were submitted to global ischaemia (35 min) followed by reperfusion (60 min), with L-lactic acid being or not administered during the first 15 min of reperfusion. L-lactic acid reduced infarct size by 23% at 20 mmol/L. An acidic Krebs induced less protection, and monocarboxylate transporter 1 (MCT1) inhibition with AR-C 141990 attenuated L-lactic acid’s protection to the level of acidic Krebs. 1 H NMR spectroscopy revealed significant metabolic changes in L-lactic acid-treated hearts, with pathway enrichment analysis showing a nearly a 3-fold enrichment in pyruvate metabolism, fatty acid biosynthesis, and gluconeogenesis, suggesting a metabolic shift. Moreover, electrically stimulated human LMS treated with L-lactic acid for 48 h exhibited improved contractility and upregulation of structural and functional cardiomyocyte components, stemness-related markers, and pro-angiogenic proteins. These findings support a cardioprotective role for L-lactic acid in both short- and long-term contexts, mediated in part by its uptake through the MCT1 transporter, induction of metabolic reprogramming, and gene expression modulation.
Open AccessL-lactic acid induces short- and long-term cardioprotective effects through MCT1 transport, induction of metabolic reprogramming, and gene expression modulation
Lactic acid is recognized as an alternative fuel source for various tissues and is acknowledged for its protective effects in the brain. However, its potential as a cardioprotective agent remains controversial. Here, we aimed to (1) evaluate the impact of acute L-lactic acid administration, given at the onset of reperfusion, on myocardial infarct size in isolated mouse hearts submitted to transient global ischemia, (2) assess the effects of chronic L-lactic acid exposure in living myocardial slices (LMS) from human hearts, and (3) elucidate the underlying mechanisms. Isolated mouse hearts were submitted to global ischaemia (35 min) followed by reperfusion (60 min), with L-lactic acid being or not administered during the first 15 min of reperfusion. L-lactic acid reduced infarct size by 23% at 20 mmol/L. An acidic Krebs induced less protection, and monocarboxylate transporter 1 (MCT1) inhibition with AR-C 141990 attenuated L-lactic acid’s protection to the level of acidic Krebs. 1 H NMR spectroscopy revealed significant metabolic changes in L-lactic acid-treated hearts, with pathway enrichment analysis showing a nearly a 3-fold enrichment in pyruvate metabolism, fatty acid biosynthesis, and gluconeogenesis, suggesting a metabolic shift. Moreover, electrically stimulated human LMS treated with L-lactic acid for 48 h exhibited improved contractility and upregulation of structural and functional cardiomyocyte components, stemness-related markers, and pro-angiogenic proteins. These findings support a cardioprotective role for L-lactic acid in both short- and long-term contexts, mediated in part by its uptake through the MCT1 transporter, induction of metabolic reprogramming, and gene expression modulation.
- Open Access
- 21 June 2023
- Published by American Chemical Society (ACS) in ACS Applied Bio Materials
- Vol. 6 (7) , 2860-2874
Conductive Bacterial Nanocellulose-Polypyrrole Patches Promote Cardiomyocyte Differentiation
The low endogenous regenerative capacity of the heart, added to the prevalence of cardiovascular diseases, triggered the advent of cardiac tissue engineering in the last decades. The myocardial niche plays a critical role in directing the function and fate of cardiomyocytes; therefore, engineering a biomimetic scaffold holds excellent promise. We produced an electroconductive cardiac patch of bacterial nanocellulose (BC) with polypyrrole nanoparticles (Ppy NPs) to mimic the natural myocardial microenvironment. BC offers a 3D interconnected fiber structure with high flexibility, which is ideal for hosting Ppy nanoparticles. BC-Ppy composites were produced by decorating the network of BC fibers (65 ± 12 nm) with conductive Ppy nanoparticles (83 ± 8 nm). Ppy NPs effectively augment the conductivity, surface roughness, and thickness of BC composites despite reducing scaffolds' transparency. BC-Ppy composites were flexible (up to 10 mM Ppy), maintained their intricate 3D extracellular matrix-like mesh structure in all Ppy concentrations tested, and displayed electrical conductivities in the range of native cardiac tissue. Furthermore, these materials exhibit tensile strength, surface roughness, and wettability values appropriate for their final use as cardiac patches. In vitro experiments with cardiac fibroblasts and H9c2 cells confirmed the exceptional biocompatibility of BC-Ppy composites. BC-Ppy scaffolds improved cell viability and attachment, promoting a desirable cardiomyoblast morphology. Biochemical analyses revealed that H9c2 cells showed different cardiomyocyte phenotypes and distinct levels of maturity depending on the amount of Ppy in the substrate used. Specifically, the employment of BC-Ppy composites drives partial H9c2 differentiation toward a cardiomyocyte-like phenotype. The scaffolds increase the expression of functional cardiac markers in H9c2 cells, indicative of a higher differentiation efficiency, which is not observed with plain BC. Our results highlight the remarkable potential use of BC-Ppy scaffolds as a cardiac patch in tissue regenerative therapies.
- 21 June 2023
- Published by American Chemical Society (ACS) in ACS Applied Bio Materials
- Vol. 6 (7) , 2860-2874
Open AccessConductive Bacterial Nanocellulose-Polypyrrole Patches Promote Cardiomyocyte Differentiation
The low endogenous regenerative capacity of the heart, added to the prevalence of cardiovascular diseases, triggered the advent of cardiac tissue engineering in the last decades. The myocardial niche plays a critical role in directing the function and fate of cardiomyocytes; therefore, engineering a biomimetic scaffold holds excellent promise. We produced an electroconductive cardiac patch of bacterial nanocellulose (BC) with polypyrrole nanoparticles (Ppy NPs) to mimic the natural myocardial microenvironment. BC offers a 3D interconnected fiber structure with high flexibility, which is ideal for hosting Ppy nanoparticles. BC-Ppy composites were produced by decorating the network of BC fibers (65 ± 12 nm) with conductive Ppy nanoparticles (83 ± 8 nm). Ppy NPs effectively augment the conductivity, surface roughness, and thickness of BC composites despite reducing scaffolds' transparency. BC-Ppy composites were flexible (up to 10 mM Ppy), maintained their intricate 3D extracellular matrix-like mesh structure in all Ppy concentrations tested, and displayed electrical conductivities in the range of native cardiac tissue. Furthermore, these materials exhibit tensile strength, surface roughness, and wettability values appropriate for their final use as cardiac patches. In vitro experiments with cardiac fibroblasts and H9c2 cells confirmed the exceptional biocompatibility of BC-Ppy composites. BC-Ppy scaffolds improved cell viability and attachment, promoting a desirable cardiomyoblast morphology. Biochemical analyses revealed that H9c2 cells showed different cardiomyocyte phenotypes and distinct levels of maturity depending on the amount of Ppy in the substrate used. Specifically, the employment of BC-Ppy composites drives partial H9c2 differentiation toward a cardiomyocyte-like phenotype. The scaffolds increase the expression of functional cardiac markers in H9c2 cells, indicative of a higher differentiation efficiency, which is not observed with plain BC. Our results highlight the remarkable potential use of BC-Ppy scaffolds as a cardiac patch in tissue regenerative therapies.